iCrowdNewswire Jan 21, 2021 11:22 AM ET
Bile duct cancer is a form of cancer that occurs in the slender tubes which carry bile through the liver. It is a rare yet aggressive type of cancer. Some of its symptoms include nausea and vomiting, fever, loss of appetite, weight loss, abdominal pain, dark urine, light-colored stools, jaundice, and intensely itchy skin. The global bile duct cancer market is likely to grow at a 9.2% CAGR between 2017- 2023, according to the recent Market Research Future (MRFR) report.
Request Sample Copy:
The MRFR report provides an inclusive segmental analysis of the global bile duct cancer market based on end users, type, treatment, and diagnosis.
By type, the bile duct cancer market is segmented into extrahepatic, intrahepatic, and others.
By diagnosis, the bile duct cancer market is segmented into surgery, abdominal imaging, blood tests, and others. The abdominal imaging segment is again segmented into magnetic resonance cholangiopancreatography (MRCP), percutaneous transhepatic cholangiography (PTC), endoscopic retrograde cholangiopancreatography (ERCP), and others.
By treatment, the bile duct cancer market is segmented into radiotherapy, chemotherapy, and others. The chemotherapy segment is again segmented into cisplatin, gemcitabine, 5-fluorouracil, and others. Of these, the 5-fluorouracil segment will lead the market over the forecast period.
By end users, the bile duct cancer market is segmented into research organizations, academic institutes, hospitals and clinics, and others. Of these, the hospitals will have lions share over the forecast period.
Based on the region, the global bile duct cancer market covers the recent trends and growth opportunities across Europe, the Americas, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, the Americas will spearhead the market over the forecast period. Factors adding market growth include the presence of a well-established healthcare industry, increasing healthcare expenditure, a rising number of patients, and rising cases of bile duct cancer. Additional factors adding market growth include growing public-private investments, increasing awareness programs, and ongoing research activities. Canada & the US are the key contributors in the region for the rising cases of bile duct cancer.
The global bile duct cancer market is the APAC region is predicted to grow at a quick face over the forecast period. Factors fuelling the market growth in the region include the presence of key suppliers and manufacturers of bile duct cancer drugs, increasing fiscal investments by government, increasing cases of liver infections, and huge patient population pool. China, as well as India, are the key contributors in the region.
The global bile duct cancer market in the MEA is predicted to have the smallest share over the forecast period for the presence of a poor economy, particularly in the Africa region. The Middle East will have a good share in the market for the huge healthcare expenditure & the presence of a well-established healthcare sector.
Leading players profiled in the global bile duct cancer market report include Mylan N.V. (U.S.), Fresenius Kabi AG (Europe), Sanofi (Europe), Eli Lilly and Company. (U.S.), Teva Pharmaceutical Industries Ltd. (Middle East), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd (Europe), and Pfizer Inc. (U.S.).
Browse Full Report @
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312
Email: [email protected]
Keywords: Bile Duct Cancer Market, Bile Duct Cancer Market scope, Bile Duct Cancer Market size, Bile Duct Cancer Market share, Bile Duct Cancer Market demand, Bile Duct Cancer Market growth